Dr. Brian Shuch, MD
Claim this profileUCLA / Jonsson Comprehensive Cancer Center
Area of expertise
Kidney Cancer
Brian Shuch, MD has run 6 trials for Kidney Cancer. Some of their research focus areas include:
Renal Cell Carcinoma
Brian Shuch, MD has run 4 trials for Renal Cell Carcinoma. Some of their research focus areas include:
Affiliated Hospitals
UCLA / Jonsson Comprehensive Cancer Center
UCLA
Clinical Trials Brian Shuch, MD is currently running
Immunotherapy With or Without Surgery
for Kidney Cancer
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, pembrolizumab, and avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Surgery to remove the kidney, called a nephrectomy, is also considered standard of care; however, doctors who treat kidney cancer do not agree on its benefits. It is not yet known if the addition of surgery to an immunotherapy-based drug combination works better than an immunotherapy-based drug combination alone in treating patients with kidney cancer.
Recruiting
2 awards
Phase 3
16 criteria
SPECT/CT
for Kidney Cancer
This trial studies how well technetium Tc-99m sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) works on clinical decision making in patients with kidney tumors. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT/CT may be a less invasive way to check for kidney tumors.
Recruiting
1 award
N/A
10 criteria
More about Brian Shuch, MD
Clinical Trial Related
4 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Brian Shuch, MD has experience with
- Zirconium Zr 89 Girentuximab
- Pamiparib
- Temozolomide
- Technetium Tc-99m Sestamibi
- Avelumab
- Axitinib
Breakdown of trials Brian Shuch, MD has run
Kidney Cancer
Renal Cell Carcinoma
Kidney Tumors
HLRCC
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Brian Shuch, MD specialize in?
Brian Shuch, MD focuses on Kidney Cancer and Renal Cell Carcinoma. In particular, much of their work with Kidney Cancer has involved Stage IV patients, or patients who are FH.
Is Brian Shuch, MD currently recruiting for clinical trials?
Yes, Brian Shuch, MD is currently recruiting for 3 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Brian Shuch, MD has studied deeply?
Yes, Brian Shuch, MD has studied treatments such as Zirconium Zr 89 Girentuximab, Pamiparib, Temozolomide.
What is the best way to schedule an appointment with Brian Shuch, MD?
Apply for one of the trials that Brian Shuch, MD is conducting.
What is the office address of Brian Shuch, MD?
The office of Brian Shuch, MD is located at: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California 90095 United States. This is the address for their practice at the UCLA / Jonsson Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.